The natural history of body-first versus brain-first Parkinson's disease subtypes
- PMID: 40204988
- PMCID: PMC11982158
- DOI: 10.1007/s00415-025-13050-y
The natural history of body-first versus brain-first Parkinson's disease subtypes
Abstract
Background: Several lines of evidence support the hypothesis of brain-first and body-first Parkinson's disease (PD) subtypes, characterized by distinct origins of α-synuclein pathology. However, data on premotor non-motor burden and motor progression in these subtypes remain inconsistent.
Objective: To analyze the natural history of body-first versus brain-first PD subtypes.
Methods: Data from 400 PD patients enrolled at a single Italian center were analyzed. All patients underwent a standardized retrospective baseline assessment of premotor and motor symptoms at onset and were prospectively followed. Premotor REM sleep behavior disorder (RBD), considered a prodromal phenotype of the body-first subtype, was used to divide patients into two groups: 81 patients with probable premotor RBD (PDpreRBD+) and 319 patients without (PDpreRBD-).
Results: At motor onset, PDpreRBD+ patients were older than PDpreRBD- patients, exhibited less tremor, and more frequently presented with bilateral motor symptoms. PDpreRBD+ patients also reported a greater burden of premotor symptoms, including hyposmia, cognitive impairment, pain, constipation, and other dysautonomic symptoms. Over the follow-up period, PDpreRBD+ patients progressed more rapidly to Hoehn and Yahr stage 3, even after adjusting for sex, years of schooling, age at motor onset, and initial motor phenotype.
Conclusions: Our results align with the hypothesis of brain-first and body-first PD subtypes, providing novel insights into their different premotor non-motor burden and motor progression trajectories.
Keywords: Body-first; Brain-first; Motor progression; Parkinson’s disease subtypes; Premotor symptoms; REM sleep behavior disorder (RBD).
© 2025. The Author(s).
Conflict of interest statement
Declarations. Conflict of interest: The authors have no competing interests to declare that are relevant to the content of this article. Ethical approval: This study was conducted in accordance with the principles of the Declaration of Helsinki. Ethical approval was waived by the local ethical review board because all procedures performed were part of routine clinical care. Consent to participate: Informed consent was obtained from all individual participants included in the study.
Figures
References
-
- Fereshtehnejad SM, Romenets SR, Anang JB, Latreille V, Gagnon JF, Postuma RB (2015) New clinical subtypes of parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol 72(8):863–873. 10.1001/jamaneurol.2015.0703 - PubMed
-
- Thenganatt MA, Jankovic J (2014) Parkinson disease subtypes. JAMA Neurol 71(4):499–504. 10.1001/jamaneurol.2013.6233 - PubMed
-
- Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211. 10.1016/s0197-4580(02)00065-9 - PubMed
-
- Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, Sasse J, Boyer S, Shirohi S, Brooks R, Eschbacher J, White CL 3rd, Akiyama H, Caviness J, Shill HA, Connor DJ, Sabbagh MN, Walker DG, Arizona Parkinson’s Disease Consortium (2009) Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 117(6):613–634. 10.1007/s00401-009-0538-8 - PMC - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
